Bimal Bhindi1, Jeffrey Graham2, J Connor Wells3, Ziad Bakouny4, Frede Donskov5, Anna Fraccon6, Felice Pasini7, Jae Lyun Lee8, Naveen S Basappa9, Aaron Hansen10, Christian K Kollmannsberger11, Ravindran Kanesvaran12, Takeshi Yuasa13, D Scott Ernst14, Sandy Srinivas15, Brian I Rini16, Isaac Bowman17, Sumanta K Pal18, Toni K Choueiri4, Daniel Y C Heng3. 1. University of Calgary, Calgary, AB, Canada; Southern Alberta Institute of Urology, Calgary, AB, Canada. Electronic address: bimal.bhindi@gmail.com. 2. CancerCare Manitoba, Winnipeg MB, Canada. 3. Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada. 4. Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 5. Aarhus University Hospital, Aarhus, Denmark. 6. CDC Pererzoli, Peschiera del Garda, Italy. 7. Oncologia Medica Ospedale Santa Maria della Misericordia, Rovigo, Italy. 8. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. 9. University of Alberta, Edmonton, AB, Canada. 10. Princess Margaret Cancer Centre, Toronto, Canada. 11. British Columbia Cancer Agency, Vancouver, Canada. 12. National Cancer Centre Singapore, Singapore. 13. Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. 14. Western University, London, ON, Canada. 15. Stanford Medical Center, Stanford, CA, USA. 16. Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. 17. UT Southwestern Medical Center, Dallas, TX, USA. 18. City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Abstract
BACKGROUND: The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit. OBJECTIVE: We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to sunitinib alone, and outcomes of CN followed by sunitinib. DESIGN, SETTING, AND PARTICIPANTS: We used the prospectively maintained International mRCC Database Consortium (IMDC) database to identify patients with newly diagnosed mRCC (2006-2018). INTERVENTION: Sunitinib alone, upfront CN followed by sunitinib, sunitinib followed by dCN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall survival (OS) and time to sunitinib treatment failure (TTF). Kaplan-Meier and multivariable Cox regression analyses were performed; dCN was analyzed as a time-varying covariate to account for immortal time bias. RESULTS AND LIMITATIONS: We evaluated 1541 patients, of whom 651 (42%) received sunitinib alone, 805 (52%) underwent CN followed by sunitinib, and 85 (5.5%) received sunitinib followed by dCN, at a median of 7.8 mo from diagnosis. Median OS periods for patients treated with sunitinib alone, CN followed by sunitinib, and sunitinib followed by dCN were 10, 19, and 46 mo, respectively, while the median TTF values were 4, 8, and 13 mo, respectively. In multivariable regression analyses, sunitinib followed by dCN was significantly associated with improved OS (hazard ratio [HR] = 0.45, 95% confidence interval [CI] 0.33-0.60, p < 0.001) and TTF (HR = 0.62, 95% CI 0.46-0.85, p = 0.003) versus sunitinib alone. Among CN-treated patients, sunitinib followed by dCN was associated with improved OS (HR = 0.52, 95% CI 0.39-0.70, p < 0.001) and TTF (HR = 0.71, 95% CI 0.56-0.90, p = 0.005) compared with upfront CN followed by sunitinib. In various sensitivity analyses, dCN remained significantly associated with improved OS and TTF. CONCLUSIONS: Patients who received dCN were carefully selected and achieved long OS. With these benchmark outcomes, optimal selection criteria need to be identified and confirmation of the role of dCN in a clinical trial is warranted. PATIENT SUMMARY: We characterized benchmark survival outcomes for patients with metastatic kidney cancer treated with sunitinib alone, nephrectomy (kidney removal) followed by sunitinib, and sunitinib followed by nephrectomy. Patients who had their nephrectomy after an initial course of sunitinib had prolonged survival.
BACKGROUND: The use of cytoreductive nephrectomy (CN) selectively for patients who show a favorable response to upfront systemic therapy may be an approach to select optimal candidates with metastatic renal cell carcinoma (mRCC) who are most likely to benefit. OBJECTIVE: We sought to characterize outcomes of deferred CN (dCN) after upfront sunitinib, outcomes relative to sunitinib alone, and outcomes of CN followed by sunitinib. DESIGN, SETTING, AND PARTICIPANTS: We used the prospectively maintained International mRCC Database Consortium (IMDC) database to identify patients with newly diagnosed mRCC (2006-2018). INTERVENTION: Sunitinib alone, upfront CN followed by sunitinib, sunitinib followed by dCN. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Outcomes were overall survival (OS) and time to sunitinib treatment failure (TTF). Kaplan-Meier and multivariable Cox regression analyses were performed; dCN was analyzed as a time-varying covariate to account for immortal time bias. RESULTS AND LIMITATIONS: We evaluated 1541 patients, of whom 651 (42%) received sunitinib alone, 805 (52%) underwent CN followed by sunitinib, and 85 (5.5%) received sunitinib followed by dCN, at a median of 7.8 mo from diagnosis. Median OS periods for patients treated with sunitinib alone, CN followed by sunitinib, and sunitinib followed by dCN were 10, 19, and 46 mo, respectively, while the median TTF values were 4, 8, and 13 mo, respectively. In multivariable regression analyses, sunitinib followed by dCN was significantly associated with improved OS (hazard ratio [HR] = 0.45, 95% confidence interval [CI] 0.33-0.60, p < 0.001) and TTF (HR = 0.62, 95% CI 0.46-0.85, p = 0.003) versus sunitinib alone. Among CN-treated patients, sunitinib followed by dCN was associated with improved OS (HR = 0.52, 95% CI 0.39-0.70, p < 0.001) and TTF (HR = 0.71, 95% CI 0.56-0.90, p = 0.005) compared with upfront CN followed by sunitinib. In various sensitivity analyses, dCN remained significantly associated with improved OS and TTF. CONCLUSIONS:Patients who received dCN were carefully selected and achieved long OS. With these benchmark outcomes, optimal selection criteria need to be identified and confirmation of the role of dCN in a clinical trial is warranted. PATIENT SUMMARY: We characterized benchmark survival outcomes for patients with metastatic kidney cancer treated with sunitinib alone, nephrectomy (kidney removal) followed by sunitinib, and sunitinib followed by nephrectomy. Patients who had their nephrectomy after an initial course of sunitinib had prolonged survival.
Authors: Charles Van Praet; Charlotte Slots; Nikhil Vasdev; Sylvie Rottey; Valérie Fonteyne; Iulia Andras; Maarten Albersen; Gert De Meerleer; Axel Bex; Karel Decaestecker Journal: Turk J Urol Date: 2021-02
Authors: Alberto C Pieretti; Daniel D Shapiro; Mary E Westerman; Hyunsoo Hwang; Xuemei Wang; Luis A Segarra; Matthew T Campbell; Nizar M Tannir; Eric Jonasch; Surena F Matin; Christopher G Wood; Jose A Karam Journal: Urol Oncol Date: 2021-09-20 Impact factor: 2.954
Authors: Pooja Ghatalia; Elizabeth A Handorf; Daniel M Geynisman; Mengying Deng; Matthew R Zibelman; Philip Abbosh; Fern Anari; Richard E Greenberg; Rosalia Viterbo; David Chen; Marc C Smaldone; Alexander Kutikov; Robert G Uzzo Journal: J Urol Date: 2022-02-25 Impact factor: 7.600
Authors: Stepan M Esagian; Ioannis A Ziogas; Dimitrios Kosmidis; Mohammad D Hossain; Nizar M Tannir; Pavlos Msaouel Journal: Cancers (Basel) Date: 2021-02-09 Impact factor: 6.639
Authors: Alexandra L Tabakin; Mark N Stein; Christopher B Anderson; Charles G Drake; Eric A Singer Journal: Transl Cancer Res Date: 2020-11 Impact factor: 1.241
Authors: Marco Stellato; Daniele Santini; Elena Verzoni; Ugo De Giorgi; Francesco Pantano; Chiara Casadei; Giuseppe Fornarini; Marco Maruzzo; Andrea Sbrana; Giuseppe Di Lorenzo; Mariella Soraru; Emanuele Naglieri; Sebastiano Buti; Rocco De Vivo; Andrea Napolitano; Francesca Vignani; Claudia Mucciarini; Francesco Grillone; Giandomenico Roviello; Marilena Di Napoli; Giuseppe Procopio Journal: Front Oncol Date: 2021-06-08 Impact factor: 6.244